• AI in Healthcare: How To Assess What Works

    Bio-IT World| At a panel discussion this week at the ViVE conference in Nashville, Tenn., researchers and physicians discussed the promise and hype of AI. Moderated by Alexander Morgan, partner at Khosla Ventures, the discussion was wide ranging and discussed the AI tools ready for use by physicians; which classes of AI are not yet delivering; and how to assess what’s right for you.

    Feb 18, 2025

  • Ultima Genomics Sequencing Platform Selected for UK Biobank Study

    Bio-IT World| Last month, Ultima Genomics announced that their UG 100 sequencing platform was selected by UK Biobank to be used in their human proteomics study, which is anticipated to be the largest and most comprehensive proteomics study to date. The study is intended to quantify more than 5,400 protein markers across 600,000 samples, which will help researchers understand how protein levels fluctuate over time and how these changes correlate with disease progression and aging.

    Feb 14, 2025

  • Epigenetics Alone Can Alter Cancer Susceptibility

    Bio-IT World| Evidence is emerging that epigenetic differences prior to birth can signal the type of cancer that occurs decades later by dictating which mutated cells turn into a tumor. It is “underappreciated” that most otherwise healthy people are walking around with cancer-causing mutations that their body suppresses unless their built-in defense system mysteriously fails.

    Feb 13, 2025

  • Lifebit, Psifas Partner for Israeli Genomic Medicine Initiative

    Bio-IT World | On the heels of its announced collaboration with 23andMe, Lifebit, has announced a long-term partnership with Psifas, Israeli Genomic Medicine Initiative. This collaboration will empower groundbreaking advancements in personalized medicine by providing a secure and unified platform for clinical-genomic research across Israel’s diverse population.

    Feb 10, 2025

  • Crystal Ball: At JP Morgan, Companies Predict Trump Administration Impacts

    Bio-IT World| Market questions always arise with the changing of presidential administration in the United States, though this year’s uncertainty seems a bit heightened. Expected outlooks to NIH funding and other regulatory and even Department of Government Efficiencies (DOGE) changes came up in analyst questions after some of the presentations at the J.P. Morgan Healthcare Conference last month.

    Feb 6, 2025

  • 10X Genomics at JPM: New Products, New Sales Team, New Markets

    Bio-IT World | 10X Genomics launched a spate of new products in 2024 in both their single cell and spatial areas. “Our view is that eventually, every relevant sample will need to be analyzed with single cell and spatial context,” said Serge Saxonov, 10X CEO and co-founder, in his 2025 J.P. Morgan Healthcare Conference presentation.

    Feb 5, 2025

  • Recursion at JPM: Exscientia Merger and the Coming Virtual Cell

    Bio-IT World | Chris Gibson, CEO of Recursion, gave the company update last month at the 2025 J.P. Morgan Healthcare Conference. Gibson gave updates on several Recursion pipeline programs for indications including precision oncology, rare disease, and other indications. He also gave updates on the merger with Exscientia and the coming virtual cell.

    Feb 4, 2025